National Children's Research Centre, Dublin, Ireland; National Children's Hospital, Dublin, Ireland.
J Urol. 2012 Oct;188(4 Suppl):1485-9. doi: 10.1016/j.juro.2012.02.023. Epub 2012 Aug 17.
In recent years the endoscopic injection of dextranomer/hyaluronic acid has become an established alternative to long-term antibiotic prophylaxis and the surgical management of vesicoureteral reflux. We determined the safety and effectiveness of the endoscopic injection of dextranomer/hyaluronic acid as first line treatment for high grade vesicoureteral reflux.
Between 2001 and 2010, 1,551 children (496 male, 1,055 female, median age 1.6 years) underwent endoscopic correction of intermediate and high grade vesicoureteral reflux using dextranomer/hyaluronic acid soon after the diagnosis of vesicoureteral reflux on initial voiding cystourethrogram. Vesicoureteral reflux was unilateral in 761 children and bilateral in 790. Renal scarring was detected in 369 (26.7%) of the 1,384 patients who underwent dimercapto-succinic acid imaging. Reflux grade in the 2,341 ureters was II in 98 (4.2%), III in 1,340 (57.3%), IV in 818 (34.9%) and V in 85 (3.6%). Followup ultrasound and voiding cystourethrogram were performed 3 months after the outpatient procedure, and renal ultrasound was performed annually thereafter. Patients were followed for 3 months to 10 years (median 5.6 years).
Vesicoureteral reflux resolved after the first, second and third endoscopic injection of dextranomer/hyaluronic acid in 2,039 (87.1%), 264 (11.3%) and 38 (1.6%) ureters, respectively. Febrile urinary tract infections developed during followup in 69 (4.6%) patients. None of the patients in the series needed reimplantation of ureters or experienced any significant complications.
Our results confirm the safety and efficacy of the endoscopic injection of dextranomer/hyaluronic acid in the eradication of high grade vesicoureteral reflux. We recommend this 15-minute outpatient procedure as the first line of treatment for high grade vesicoureteral reflux.
近年来,透明质酸聚糖在治疗上已成为治疗膀胱输尿管反流的替代方案,取代了长期的抗生素预防和手术处理。我们确定了透明质酸聚糖内镜注射作为治疗高级别膀胱输尿管反流的一线治疗的安全性和有效性。
2001 年至 2010 年间,在初始排尿性膀胱尿道造影诊断为膀胱输尿管反流后不久,1551 名儿童(496 名男性,1055 名女性,中位年龄 1.6 岁)使用透明质酸聚糖进行内镜治疗,治疗中间度和高级别膀胱输尿管反流。761 名儿童为单侧反流,790 名儿童为双侧反流。在 1384 名接受二巯基丁二酸成像的患者中,发现 369 名(26.7%)存在肾瘢痕。2341 条输尿管中,反流分级 II 级 98 条(4.2%),III 级 1340 条(57.3%),IV 级 818 条(34.9%),V 级 85 条(3.6%)。门诊治疗后 3 个月进行超声和排尿性膀胱尿道造影随访,此后每年进行肾脏超声检查。患者随访 3 个月至 10 年(中位随访时间 5.6 年)。
2039 条(87.1%)、264 条(11.3%)和 38 条(1.6%)输尿管在第一次、第二次和第三次透明质酸聚糖内镜注射后,膀胱输尿管反流得到缓解。在随访期间,69 名(4.6%)患者出现发热性尿路感染。本系列中没有患者需要重新进行输尿管植入术,也没有出现任何严重并发症。
我们的结果证实了透明质酸聚糖内镜注射在消除高级别膀胱输尿管反流方面的安全性和有效性。我们建议将这一 15 分钟的门诊手术作为高级别膀胱输尿管反流的一线治疗方法。